Press Releases and Ad-hoc Announcements

26 October 2016	PR: WILEX AG: Subsidiary Heidelberg Pharma and Nordic Nanovector Enter into Collaboration to Develop Novel Antibody Drug Conjugates (ADC)	PDF	Read More
13 October 2016	PR: WILEX AG: Interim Management Statement on the First Nine Months of 2016	PDF	Read More
11 October 2016	AH: WILEX AG secures further financing with shareholder loan based on an existing financing commitment	PDF	Read More
27 September 2016	PR: WILEX AG: Subsidiary Heidelberg Pharma contracts Suisse CDMO Celonic for antibody cell line development and antibody production	PDF	Read More
19 September 2016	PR: WILEX AG: Subsidiary Heidelberg Pharma Signs Option Agreement with Max Delbrück Center	PDF	Read More
14 July 2016	PR: WILEX publishes Half-yearly Financial Report	PDF	Read More
28 June 2016	PR: WILEX AG: European Patent Office grants patent for the chemical synthetic building block dihydroxyisoleucine for the production of Amanitin	PDF	Read More
14 June 2016	PM: Advanced Proteome Therapeutics Corporation and WILEX subsidiary Heidelberg Pahrma collaborate to create improve cancer therapeutics	PDF	Read More
02 June 2016	AH: WILEX AG announces change on the Executive Management Board	PDF	Read More
02 June 2016	PR: WILEX AG announces change on the Executive Management Board	PDF	Read More
25 April 2016	PR: WILEX AG successfully completes capital increase	PDF	Read More
14 April 2016	PR: WILEX AG: Interim management statement on the first quarter of 2016	PDF	Read More
06 April 2016	PR: WILEX AG plans change on Supervisory Board	PDF	Read More
22 March 2016	PR: WILEX announces financial figures for the 2015 financial year and reports on course of business	PDF	Read More
02 February 2016	PR: WILEX AG: US-patent office granted patent for amatoxin conjugates for tumour therapy	PDF	Read More
13 January 2016	PR: WILEX’s partner Link Health submits IND application for clinical Phase I with the uPA inhibitor MESUPRON® in China	PDF	Read More

© Heidelberg Pharma AG. All rights reserved.